Biomedical Engineering Reference
In-Depth Information
132. Spratlin J, Sangha R, Glubrecht D, Dabbagh L, Young JD, Dumontet C, Cass C, Lai R,
Mackey JR. 2004. The absence of human equilibrative nucleoside transporter 1 is associ-
ated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma.
Clin Cancer Res 10(20):6956-6961.
133. Giovannetti E, Del Tacca M, Mey V, Funel N, Nannizzi S, Ricci S, Orlandini C, Boggi
U, Campani D, Del Chiaro M, et al. 2006. Transcription analysis of human equilibra-
tive nucleoside transporter-1 predicts survival in pancreas cancer patients treated with
gemcitabine. Cancer Res 66(7):3928-3935.
134. Rongen GA, Smits P, Ver Donck K, Willemsen JJ, De Abreu RA, Van Belle H, Thien T.
1995. Hemodynamic and neurohumoral effects of various grades of selective adenosine
transport inhibition in humans. Implications for its future role in cardioprotection. J Clin
Invest 95(2):658-668.
135. Parkinson FE, Rudolphi KA, Fredholm BB. 1994. Propentofylline: a nucleoside transport
inhibitor with neuroprotective effects in cerebral ischemia. Gen Pharmacol 25(6):1053-
1058.
136. Reiman T, Clarke ML, Dabbagh L, Vsianska M, Coupland RW, Belch AR, Baldwin SA,
Young JD, Cass CE, Mackey JR. 2002. Differential expression of human equilibrative nu-
cleoside transporter 1 (hENT1) protein in the Reed-Sternberg cells of Hodgkin's disease.
Leuk Lymphoma 43(7):1435-1440.
137. Mackey JR, Jennings LL, Clarke ML, Santos CL, Dabbagh L, Vsianska M, Koski SL,
Coupland RW, Baldwin SA, Young JD, Cass CE. 2002. Immunohistochemical variation
of human equilibrative nucleoside transporter 1 protein in primary breast cancers. Clin
Cancer Res 8(1):110-116.
138. Leabman MK, Huang CC, DeYoung J, Carlson EJ, Taylor TR, de la Cruz M, Johns SJ,
Stryke D, Kawamoto M, Urban TJ, et al. 2003. Pharmacogenetics of Membrane Trans-
porters. I: Natural variation in human membrane transporter genes reveals evolutionary
and functional constraints. Proc Natl Acad SciUSA100(10):5896-5901.
139. Gray JH, Mangravite LM, Owen RP, Urban TJ, Chan W, Carlson EJ, Huang CC,
Kawamoto M, Johns SJ, Stryke D, Ferrin TE, Giacomini KM. 2004. Functional and
genetic diversity in the concentrative nucleoside transporter, CNT1, in human popula-
tions. Mol Pharmacol 65(3):512-519.
140. Owen RP, Lagpacan LL, Taylor TR, de la Cruz M, Huang CC, Kawamoto M, Johns SJ,
Stryke D, Ferrin TE, Giacomini KM. 2006. Functional characterization and haplotype
analysis of polymorphisms in the human equilibrative nucleoside transporter, ENT2. Drug
Metab Dispos 34(1):12-15.
141. Badagnani I, Chan W, Castro RA, Brett CM, Huang CC, Stryke D, Kawamoto M, Johns
SJ, Ferrin TE, Carlson EJ, Burchard EG, Giacomini KM. 2005. Functional analysis of
genetic variants in the human concentrative nucleoside transporter 3 (CNT3; SLC28A3).
Pharmacogenom J 5(3):157-165.
142. Osato DH, Huang CC, Kawamoto M, Johns SJ, Stryke D, Wang J, Ferrin TE, Herskowitz
I, Giacomini KM. 2003. Functional characterization in yeast of genetic variants in the
human equilibrative nucleoside transporter, ENT1. Pharmacogenetics 13(5):297-301.
143. Myers SN, Goyal RK, Roy JD, Fairfull LD, Wilson JW, Ferrell RE. 2006. Functional single
nucleotide polymorphism haplotypes in the human equilibrative nucleoside transporter
1. Pharmacogenet Genom 16(5):315-320.
Search WWH ::
Custom Search